Vicarius Pharma

A NOVEL OPTION TO LAUNCH IN EUROPE Vicarius Pharma delivers emerging bio-pharma companies greater strategic choice in bringing late-stage (end of phase 3/registration phase) specialty, orphan/rare and hospital therapeutics to the European market. Vicarius provides companies with an option beyond the binary decision to "go it alone" in Europe versus... out-licensing to an established pharma company, with the loss of control this entails. When entering Europe with Vicarius Pharma, partner companies avoid the risk and costs of trying to build their own organization but don't lose strategic control over their asset, as they would in a traditional out-licensing deal. Our business model allows them the option to recapture the asset at any time of the partnership, for instance if they decide to go direct in Europe or on a change of control.Read More